The first licensed dengue vaccine: an important tool for integrated preventive strategies against dengue virus infection

Expert Review of Vaccines

Volumn 15, Issue 7, 2016, Pages 795-798

  Pitisuttithum, Punnee ^a   Bouckenooghe, Alain ^b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b Sanofi Pasteur   (Singapore)

Author keywords

CYD TDV; Dengue; health planning; preventive strategies; vaccine

Indexed keywords

DENGUE VACCINE; LIVE VACCINE; RECOMBINANT VACCINE; CYD-TDV VACCINE;

DECISION MAKING; DENGUE; DISEASE SURVEILLANCE; DRUG SURVEILLANCE PROGRAM; EDITORIAL; FINANCIAL MANAGEMENT; HUMAN; INFECTION CONTROL; NONHUMAN; PRIORITY JOURNAL; VACCINATION; YELLOW FEVER VIRUS; DENGUE VIRUS; DRUG APPROVAL; IMMUNOLOGY; LICENSING; PATHOGENICITY; TRANSMISSION;

DENGUE; DENGUE VACCINES; DENGUE VIRUS; DRUG APPROVAL; HUMANS; LICENSURE; VACCINATION; VACCINES, ATTENUATED;

EID: 84975487889     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1080/14760584.2016.1189331     Document Type: Editorial

References (25)

1. S.Bhatt, P.W.Gething, O.J.Brady, et al. The global distribution and burden of dengue. Nature. 2013;496(7446):504–507.• Review of the Global distribution of dengue worldwide.
2. B.E.Martina, P.Koraka, A.D.Osterhaus Dengue virus pathogenesis: an integrated view. Clin Microbiol Rev. 2009;22(4):564–581.
3. M.R.Karyanti, C.S.Uiterwaal, R.Kusriastuti, et al. The changing incidence of dengue haemorrhagic fever in Indonesia: a 45-year registry-based analysis. BMC Infect Dis. 2014;14:412.
4. D.S.Shepard, L.Coudeville, Y.A.Halasa, et al. Economic impact of dengue illness in the Americas. Am J Trop Med Hyg. 2011;84(2):200–207.•• Economic burden among dengue endemic countries across the America continent.
5. D.S.Shepard, E.A.Undurraga, Y.A.Halasa. Economic and disease burden of dengue in Southeast Asia. PLoS Negl Trop Dis. 2013;7(2):e2055.•• Economic burden among dengue endemic countries across Southeast Asia.
6. J.P.Messina, O.J.Brady, T.W.Scott, et al. Global spread of dengue virus types: mapping the 70 year history. Trends Microbiol. 2014;22(3):138–146.
7. B.Guy, O.Briand, J.Lang, et al. Development of the Sanofi Pasteur tetravalent dengue vaccine: one more step forward. Vaccine. 2015;33(50):7100–7111.
8. J.Poo, F.Galan, R.Forrat, et al. Live-attenuated tetravalent dengue vaccine in dengue-naive children, adolescents, and adults in Mexico City: randomized controlled phase 1 trial of safety and immunogenicity. Pediatr Infect Dis J. 2011;30(1):e9–17.
9. B.Guy, M.Saville, J.Lang. Development of Sanofi Pasteur tetravalent dengue vaccine. Hum Vaccin. 2010;6(9):696–705.
10. L.Villar, G.H.Dayan, J.L.Arredondo-Garcia, et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med. 2015;372(2):113–123.• Efficacy of tetravalent dengue vaccine manufactured by Sanofi Pasteur in Latin America.
11. M.R.Capeding, N.H.Tran, S.R.Hadinegoro, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. 2014;384(9951):1358–1365.• Efficacy of tetravalent dengue vaccine manufactured by Sanofi Pasteur in Southeast Asia.
12. S.R.Hadinegoro, J.L.Arredondo-Garcia, M.R.Capeding, et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med. 2015;373(13):1195–1206.• Long term safety from the interim and meta analysis of both efficacy trials of tetravalent dengue vaccine manufactured by Sanofi Pasteur in endemic regions.
13. B.Guy, N.Jackson. Dengue vaccine: hypotheses to understand CYD-TDV-induced protection. Nat Rev Microbiol. 2016;14(1):45–54.
14. J.K.Lim, Y.S.Lee, A.Wilder-Smith, et al. Points for consideration for dengue vaccine introduction – recommendations by the dengue vaccine initiative. Expert Rev Vaccines. 2016;15(4):529–538.• Potential consideration points before dengue vaccine introduction.
15. World Health Organization. Summary of the April 2016 meeting of the Strategic Advisory Group of Experts on immunization (SAGE). 2016 [cited 2016 Apr25]. Available from: http://www.who.int/immunization/sage/meetings/2016/april/SAGE_April_2016_Meeting_Web_summary.pdf?ua=1• Strategic Advisory committee of WHO recommendation on the use of tetravalent Sanofi Pasteur dengue vaccine.
16. L.Coudeville, N.Baurin. Potential impact of dengue vaccination: insights from the first large-scale efficacy trials. Poster presented at 64th ASTMH Annual Meeting; 2015Oct25–29; Philadelphia, PA. Poster #3234.
17. C.Mantel, S.A.Wang. The privilege and responsibility of having choices: decision-making for new vaccines in developing countries. Health Policy Plan. 2012;27(Suppl 2):ii1–4.
18. World Health Organization. School vaccination readiness assessment tool. 2013 [cited 2016 Feb3]. Available from: http://apps.who.int/iris/bitstream/10665/90566/1/WHO_IVB_13.02_eng.pdf•• School Immunization program implementation over view and challenges in different setting.
19. World Health Organization. Global Immunization Vision and Strategy. 2011 [cited 2016 Jan25]. Available form: http://www.who.int/immunization/givs/en/
20. U.Thisyakorn, M.R.Capeding, D.Y.Goh, et al. Preparing for dengue vaccine introduction in ASEAN countries: recommendations from the first ADVA regional workshop. Expert Rev Vaccines. 2014;13(5):581–587.
21. World Health Organization. Dengue haemorrhagic fever: diagnosis, treatment, prevention and control. 2nd. Geneva: World Health Organization; 1997 [cited 2015 Apr1]. Available form http://apps.who.int/iris/bitstream/10665/41988/1/9241545003_eng.pdf
22. World Health Organization. Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control. 2009 [cited 2016 Jan25]. Available from: http://www.who.int/tdr/publications/documents/dengue-diagnosis.pdf
23. E.Plennevaux, A.Sabchareon, K.Limkittikul, et al. Detection of dengue cases by serological testing in a dengue vaccine efficacy trial: utility for efficacy evaluation and impact of future vaccine introduction. Vaccine. 2016;34:2707–2712.
24. J.Torresi, R.Tapia-Conyer, H.Margolis. Preparing for dengue vaccine introduction: recommendations from the 1st dengue v2V International Meeting. PLoS Negl Trop Dis. 2013;7(9):e2261.• Consideration points for dengue vaccine introduction especially emphasize on the AEFIs.
25. World Health Organization. Principles and considerations for adding a vaccine to a national immunization programme. 2014 [cited 2016 Jan28]. Available from: http://apps.who.int/iris/bitstream/10665/111548/1/9789241506892_eng.pdf?ua=1• Guideline for introduction of new vaccine. To assist countries in making informed decisions about adding a vaccine to a national immunization programme by considering its public health priority; programmatic, economic and financial feasibility; and impact on the immunization programme and on the overall health system.